Can Vitamin D reduce heart damage in cardiac surgery

association between vitamin D administration and pathological feature of cardiac cell in patients with low Vitamin D who are candidates for coronary artery bypass graft(CABG) surgery for the first time

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180118038423N1

Enrollment

Registered

2018-12-25

Start date

2018-10-20

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Vitamin d deficiency. Condition 2: Ischemic hypertrophy heart disease. Vitamin D deficiency Ischemic cardiomyopathy

Interventions

Intervention 1: Control group: 33 patients that receive placebo for 3 days before the surgery and each day 3 doses. Intervention 2: Intervention group: A 33 patients that receive Vitamin D for 3 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients that have CABG surgery for the first time patients only with coronary surgery and no valvular surgery patients that we use cardipulmonary pump during the surgery patients with vitamin D level less than 30 ng/ml

Exclusion criteria

Exclusion criteria: Patients who have Renal failure creatinine higher than 1.5 mg/dl

Design outcomes

Primary

Measure	Time frame
Caspase 2 enzyme level. Timepoint: Right after intervention(3 days before surgery)-The day of surgery -Next day after surgery. Method of measurement: Immunohistochemstry.;Caspase 3 enzyme level. Timepoint: Right after intervention(3 days before surgery)-The day of surgery -Next day after surgery. Method of measurement: Immunohistochemistery.;Caspase 7 enzyme level. Timepoint: Right after intervention(3 days before surgery)-The day of surgery -Next day after surgery. Method of measurement: Immunohistochemistery.;IL-10 serum level. Timepoint: Right after intervention(3 days before surgery)-The day of surgery -Next day after surgery. Method of measurement: Blood test.;Insulin growth factor. Timepoint: Right after intervention(3 days before surgery)-The day of surgery -Next day after surgery. Method of measurement: blood test.	—

Measure

Time frame

Caspase 2 enzyme level. Timepoint: Right after intervention(3 days before surgery)-The day of surgery -Next day after surgery. Method of measurement: Immunohistochemstry.;Caspase 3 enzyme level. Timepoint: Right after intervention(3 days before surgery)-The day of surgery -Next day after surgery. Method of measurement: Immunohistochemistery.;Caspase 7 enzyme level. Timepoint: Right after intervention(3 days before surgery)-The day of surgery -Next day after surgery. Method of measurement: Immunohistochemistery.;IL-10 serum level. Timepoint: Right after intervention(3 days before surgery)-The day of surgery -Next day after surgery. Method of measurement: Blood test.;Insulin growth factor. Timepoint: Right after intervention(3 days before surgery)-The day of surgery -Next day after surgery. Method of measurement: blood test.

—

Secondary

Measure	Time frame
Hemorrhage after surgery. Timepoint: Right after surgery. Method of measurement: Suction.;Blood units usage. Timepoint: During the surgery and after that. Method of measurement: Number of blood units.;How lung we used the ventilator. Timepoint: Since the surgery. Method of measurement: ventilator.;Kidney damage. Timepoint: After surgery. Method of measurement: blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactErfan Tasdighi

Shahid Beheshti University of Medical Sciences

erfan.tasdighi@gmail.com+98 21 23871

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026